02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
18:27 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Adverum reviewing capsid after discontinuing AAT gene therapy

Adverum Biotechnologies Inc. (NASDAQ:ADVM) will discontinue development of gene therapy ADVM-043 to treat α-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The company said that although ADVM-043 was well tolerated among six patients in the open-label, U.S....
17:51 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Clearside discontinues combo therapy for retinal vein occlusion

Clearside Biomedical Inc. (NASDAQ:CLSD) discontinued development of Xipere (formerly CLS-TA) plus Eylea aflibercept to treat macular edema following retinal vein occlusion (RVO) after the combination missed the primary endpoint in the Phase III SAPPHIRE trial....
00:34 , Nov 3, 2018 |  BioCentury  |  Finance

Part B exposure

HHS Secretary Alex Azar's proposed changes to Medicare Part B have put at least four large biopharmas at risk of substantial U.S. revenue losses. But the lack of market reaction and the views of VCs...
19:54 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Genentech's faricimab improves BCVA in Phase II for wet AMD

Genentech Inc. reported data from the Phase II STAIRWAY trial to treat wet age-related macular degeneration (AMD) showing that faricimab (RG7716) dosed every 12 or 16 weeks led to sustained improvements in visual outcomes that...
19:52 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Eylea meets 52-week endpoint in Phase III for diabetic retinopathy subset

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said both dosing schedules of Eylea aflibercept met the 52-week primary endpoint in the Phase III PANORAMA trial for early intervention of non-proliferative diabetic retinopathy without diabetic macular edema (DME). The...
14:45 , Nov 2, 2018 |  BC Extra  |  Clinical News

Adverum reviewing capsid after discontinuing AAT gene therapy

Adverum Biotechnologies Inc. (NASDAQ:ADVM) sank $1.21 (27%) to $3.34 on Friday after it said it will discontinue development of gene therapy ADVM-043 to treat α-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The company said late Thursday...
00:23 , Oct 26, 2018 |  BC Extra  |  Company News

FDA setback, positive data for Regeneron’s Eylea

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) shares slipped on Thursday, falling $14.45 to $336.94, after the company reported a regulatory delay for a prefilled syringe of Eylea aflibercept alongside positive data for the eye drug. The company...
17:56 , Oct 25, 2018 |  BC Extra  |  Politics & Policy

Trump administration to peg Part B payments to international pricing

The new Trump administration proposal for Medicare Part B could dramatically decrease revenues for companies that are heavily dependent on those sales. Announced just two weeks before Election Day, the proposed changes to Medicare Part...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...